Ingredient or product comparison
How to Use GHK-Cu for Wound Healing Protocol: Study Comparison
In vivo dermal wound model (rats), Queensland University of Technology 200 μg/mL topical Daily for 14 days 70% increase in collagen deposition, 42% faster closure Effective at standard research concentration. Daily application required for consistent results I
This source-based comparison does not add ratings or recommend a winner.
- In vivo dermal wound model (rats), Queensland University of Technology
- 200 μg/mL topical
- Daily for 14 days
- 70% increase in collagen deposition, 42% faster closure
- Effective at standard research concentration. Daily application required for consistent results
- In vitro fibroblast culture, Journal of Investigative Dermatology
- 10 μM (approximately 340 μg/mL)
- Continuous exposure
- 3.2× increase in collagen Type I gene expression
- Gene modulation occurs at lower concentrations in vitro than required for intact tissue penetration
- Human chronic wound case series, pilot data
- 500 μg/mL topical under occlusive dressing
- Every 48 hours
- 35% faster epithelialization in non-infected wounds
- Higher concentration allows less frequent application. Occlusion critical for bioavailability
- Subcutaneous injection model (porcine), wound repair research
- 1 mg/mL injectable
- Single perilesional injection at time of wounding
- 50% reduction in scar width at 30 days
- Injectable delivery bypasses absorption barrier. Single-dose shows prolonged effect due to tissue residence time